A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Docetaxel; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 07 Dec 2016 Planned End Date changed from 1 Jan 2021 to 1 Mar 2021.
- 07 Dec 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2020.